Core Viewpoint - The stock of Te Yi Pharmaceutical experienced a decline of 2.15% on December 23, with a current price of 10.93 CNY per share and a market capitalization of 5.607 billion CNY. The company has shown a year-to-date stock price increase of 22.80% but has faced recent declines in the short term [1]. Financial Performance - For the period from January to September 2025, Te Yi Pharmaceutical achieved a revenue of 692 million CNY, representing a year-on-year growth of 51.86%. The net profit attributable to shareholders was 65.217 million CNY, showing a significant increase of 985.18% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical was 58,100, an increase of 10.11% from the previous period. The average number of tradable shares per shareholder decreased by 9.09% to 6,481 shares [2]. Dividend Distribution - Te Yi Pharmaceutical has distributed a total of 1.059 billion CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, the third-largest shareholder is the Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A, holding 3.3338 million shares. The fourth-largest is the Xingquan Hu-Shen 300 Index Enhanced (LOF) A, holding 1.9202 million shares, both of which have not changed in quantity compared to the previous period. The Hong Kong Central Clearing Limited, ranked ninth, reduced its holdings by 7.4217 million shares to 1.3696 million shares [3].

Core Viewpoint - The stock price of Te Yi Pharmaceutical has shown significant growth this year, with a year-to-date increase of 56.84% and a recent surge of 14.52% over the last five trading days [2] Group 1: Stock Performance - As of November 27, Te Yi Pharmaceutical's stock price rose by 2.57% to 13.96 CNY per share, with a trading volume of 8.83 billion CNY and a turnover rate of 17.18%, resulting in a total market capitalization of 71.62 billion CNY [1] - The company has appeared on the stock market's "Dragon and Tiger List" 12 times this year, with the most recent appearance on November 26, where it recorded a net buy of -19.39 million CNY [2] Group 2: Financial Performance - For the period from January to September 2025, Te Yi Pharmaceutical achieved a revenue of 6.92 billion CNY, reflecting a year-on-year growth of 51.86%, while the net profit attributable to shareholders reached 65.22 million CNY, marking an impressive increase of 985.18% [2] - The company has distributed a total of 10.59 billion CNY in dividends since its A-share listing, with 3.56 billion CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2] - Among the top ten circulating shareholders, the third-largest is the Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A, holding 3.33 million shares, while the fourth is the Xingquan Hu-Shen 300 Index Enhanced A, holding 1.92 million shares, both unchanged from the previous period [3]

Core Viewpoint - The stock of Te Yi Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 35.94%, indicating volatility in its market performance [1]. Company Performance - As of September 30, 2025, Te Yi Pharmaceutical reported a revenue of 6.92 billion yuan, representing a year-on-year growth of 51.86%, and a net profit attributable to shareholders of 652.17 million yuan, which is a significant increase of 985.18% compared to the previous year [2]. - The company has distributed a total of 1.059 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]. Stock Market Activity - The stock price of Te Yi Pharmaceutical is currently at 12.10 yuan per share, with a trading volume of 2.60 billion yuan and a turnover rate of 5.62%, leading to a total market capitalization of 6.207 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 17, where it recorded a net buy of -733.44 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2]. - Among the top ten circulating shareholders, notable positions include the "Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A" and "Xingquan Hu-Shen 300 Index Enhanced (LOF) A," which maintained their holdings [3].

Core Viewpoint - On October 20, Te Yi Pharmaceutical experienced a 5.3% increase in stock price, reaching 9.34 CNY per share, with a trading volume of 145 million CNY and a turnover rate of 4.26%, resulting in a total market capitalization of 4.788 billion CNY [1] Company Overview - Te Yi Pharmaceutical Group Co., Ltd. is located in Taicheng, Guangdong Province, and was established on May 23, 2002, with its listing date on July 31, 2014 [1] - The company's main business involves the research, development, production, and sales of traditional Chinese medicine, chemical preparations, and chemical raw materials [1] - The revenue composition of the company is as follows: Traditional Chinese medicine 61.00%, chemical preparations 32.61%, chemical raw materials 5.77%, and chemical products and others 0.61% [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under GF Fund holds a significant position in Te Yi Pharmaceutical [2] - GF Xinhe Mixed A (004750) held 246,200 shares in the second quarter, accounting for 0.21% of the fund's net value, ranking as the tenth largest heavy stock [2] - The estimated floating profit for today is approximately 115,700 CNY [2] - GF Xinhe Mixed A was established on January 16, 2018, with a latest scale of 171 million CNY, and has achieved a year-to-date return of 3.42% [2] - The fund manager, Wu Di, has a tenure of 5 years and 168 days, with a total asset scale of 77.42 billion CNY [2]

特一药业集团股份有限公司 股票代码：002728 股票简称：特一药业 公告编号：2025-014 关于公司药品盐酸多西环素片通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 三、对公司的影响 本次"盐酸多西环素片"仿制药质量和疗效一致性评价的通过，是公司研发能力、 生产及质量管理体系等综合实力的体现，也是国家药品监管部门对上述综合实力和产品 质量的认可；同时，也为公司后续品种通过仿制药质量和疗效一致性评价提供了重要的 宝贵经验借鉴。本次"盐酸多西环素片"通过仿制药质量和疗效一致性评价，对公司有 积极影响，有利于公司参与集采的投标，提升产品的市场竞争力，扩大产品的市场份额。 特一药业集团股份有限公司(以下简称"公司")于近日获得国家药品监督管理局核 准签发的"盐酸多西环素片"的《药品补充申请批准通知书》，经审查，上述药品通过 化学仿制药质量和疗效一致性评价。本次通过一致性评价的盐酸多西环素片共有 2 个规 格，分别为 0.05g、0.1g（其中 0.05g 规格为首家通过一致性评价，0.1g 规格为第二家 通过一致性评价），相关情况如下： | ...